Huagongshe화공사 화학 정보 인쇄 보고서 · 연구 참고용
1-(Cyclopropylmethyl)piperazine → 4-(8-((4-(cyclopropylmethyl)piperazin-1-yl)methyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine
참여 물질
| 역할 | 이름 | HCID | 투입량 |
|---|---|---|---|
| 반응물 | 1-(Cyclopropylmethyl)piperazine | HCID 965875 | — |
| 반응물 | 4-(8-(bromomethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine | HCID 59605812 | — |
| 생성물 | 4-(8-((4-(cyclopropylmethyl)piperazin-1-yl)methyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine | HCID 59605710 | — |
반응 단계
4-(8-(bromomethyl)-9-methyl-2-(2-methyl-1H-benzo[d]imidazol-1-yl)-9H-purin-6-yl)morpholine (50 mg) was reacted with 1-(cyclopropylmethyl)piperazine via General Procedure E to give 23.5 mg of 277 following reverse phase purification. MS (Q1) 502.3 (M)+
출처 및 근거
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|---|
| 특허 번호 | US08394796B2 |
| 출처 데이터셋 | uspto-grants-2013_03 |
| ORD ID | ord-488b13e4902c4556808cf5e13689542d |
| 출처 메모 | uspto-grants-2013_03 |